Heart Test Laboratories, Inc. (HSCS) Stock Forecast
HSCS analyst forecast
as of October 17, 2026- Analyst consensus
- Buy 4.00 / 5 from 1 analysts
- Price target
- $12.00 average of analyst targets
- Upside to target
- +297.4% from the latest close
- Next earnings
- —
- 52-week range
- $1.67 – $5.20
HSCS analyst ratings
1 analystsNumber of analysts at each rating.
HSCS price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
HSCS earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Oct '26) | −$0.62 | −$0.62 | −$0.62 | −$0.85 | +27.1% | 1 |
| Next quarter (Jan '27) | −$0.61 | −$0.61 | −$0.61 | −$0.63 | +3.2% | 1 |
| Current fiscal year (FY2027) | −$2.46 | −$2.46 | −$2.46 | −$3.48 | +29.3% | 1 |
| Next fiscal year (FY2028) | −$1.75 | −$1.75 | −$1.75 | −$2.46 | +28.9% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
HSCS revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Oct '26) | $0 | $0 | $0 | −100.0% | 1 |
| Next quarter (Jan '27) | $5,000 | $5,000 | $5,000 | 0.0% | 1 |
| Current fiscal year (FY2027) | $17,100 | $17,100 | $17,100 | +295.8% | 1 |
| Next fiscal year (FY2028) | $3.1M | $3.1M | $3.1M | +18,321.0% | 1 |
HSCS EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
HSCS revenue: reported and forecast
HSCS EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Oct '26) | −$0.69 | −$0.65 | −$0.65 | −$0.62 | −$0.62 | −10.8% | 1 up · 0 down |
| Next quarter (Jan '27) | −$0.72 | −$0.66 | −$0.66 | −$0.61 | −$0.61 | −15.3% | 1 up · 0 down |
| Current fiscal year (FY2027) | −$2.83 | −$2.62 | −$2.62 | −$2.46 | −$2.46 | −12.9% | 1 up · 0 down |
| Next fiscal year (FY2028) | −$1.93 | −$1.93 | −$1.86 | −$1.86 | −$1.75 | −9.3% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
HSCS earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; HSCS beat in 6 of 12.
What analysts expect from HSCS
1 analysts cover Heart Test Laboratories; their consensus rating is buy (4.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $12.00, 297.4% above the latest close of $3.02. Analysts expect earnings of −$2.46 per share for FY2027, +29.3% from a year earlier. For FY2028 the average estimate is −$1.75 per share on revenue of $3.1 million. Heart Test Laboratories beat the EPS estimate in 6 of the last 12 quarters.
Related: HSCS income statement, HSCS key metrics, HSCS chart. See the HSCS stock overview for the latest quote and news.
HSCS forecast FAQ
What is Heart Test Laboratories's price target?
The average analyst price target for Heart Test Laboratories is $12.00, 297.4% above the latest close of $3.02.
Is Heart Test Laboratories a buy, hold or sell?
Of 1 analysts covering Heart Test Laboratories, 0 rate it a strong buy, 1 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Heart Test Laboratories's EPS forecast?
Analysts forecast −$2.46 per share for FY2027 (range −$2.46 to −$2.46); for FY2028 the estimate is −$1.75.
What is Heart Test Laboratories's revenue forecast?
The average revenue estimate for FY2027 is $0.0 million, growth of 295.8%; for FY2028 it is $3.1 million.
Does Heart Test Laboratories usually beat earnings estimates?
Heart Test Laboratories reported EPS at or above the analyst estimate in 6 of the last 12 quarters.